Sigma Square Capital

Founded 2016


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 10
Average round size
The average size of a deal this fund participated in
Portfolio companies 13
Rounds per year 2.00
Lead investments 2
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Artificial Intelligence
  • Software
  • Health Diagnostics
  • Automotive

In 2016 was created Sigma Square Capital, which is appeared as VC. The fund was located in Asia if to be more exact in China. The main office of represented VC is situated in the Beijing.

Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. This Sigma Square Capital works on 11 percentage points less the average amount of lead investments comparing to the other organizations.

Besides them, we counted 3 critical employees of this fund in our database.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Sigma Square Capital, startups are often financed by ZhenFund, Yueyin Venture Capital, Pan-Lin Asset Management. The meaningful sponsors for the fund in investment in the same round are Lightspeed China Partners, China Growth Capital, Zhonglu Capital. In the next rounds fund is usually obtained by Xiaopeng He, Qiming Venture Partners, OceanIQ Capital.

The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Novogene,, Liking Fit. Among the most popular fund investment industries, there are Advertising, Fitness. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$93M22 Feb 2021 Woburn, Massachusetts, United States


$100M13 Mar 2020 Qingdao, Shandong, China

Artificial Intelligence
04 Mar 2020 China, Wuwei


Artificial Intelligence
$15M17 Jul 2019 China, Wuwei, China

$6M18 Dec 2018 China, Shanghai

No Panda Culture (Bukongwenhua)

Customer Service
Media and Entertainment
Social Media
$9M16 Sep 2017 Dongcheng District, Beijing, China


Consumer Goods
Food and Beverage
$3M04 Sep 2017 China, Beijing

DeePhi Tech

Information Services
Information Technology
18 May 2017 China, Beijing


Health Diagnostics
06 Mar 2017 China, Beijing
ABclonal Biotechnology Completes $93 Million Series C Financing

– ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital.
– Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.
– ABclonal Biotechnology, parent company of Massachusetts-based life science research and diagnostic reagents manufacturer, ABclonal Technology, will use the additional funding to accelerate the company’s research and development pipeline for in vitro diagnostic raw materials and rapidly expand production capabilities of its research reagent products and services.
– ABclonal is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development. This will be the company’s first step toward using the $92.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sigma Square Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: